52W $0.73 – $1.42
RenovoRx delivered strong revenue growth in FY2025 from increased adoption and repeat use of RenovoCath, but expanded operating losses reflect continued investment in commercial infrastructure amid ongoing clinical development.
Revenue breakdown: All Other Segments (100%).
RenovoRx delivered strong revenue growth in FY2025 from increased adoption and repeat use of RenovoCath, but expanded operating losses reflect continued investment in commercial infrastructure amid ongoing clinical development.
Revenue by Segment